Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1807

Showing 51-75 of 1807 citing articles:

Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
Ryan P. Wurz, Huan Rui, Ken Dellamaggiore, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 51
A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy
Yaping Wu, Xiaowei Chang, Guizhu Yang, et al.
Advanced Materials (2023) Vol. 35, Iss. 12
Open Access | Times Cited: 50
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 50
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
Alastair Davies, Amina Zoubeidi, Himisha Beltran, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1771-1788
Closed Access | Times Cited: 49
The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies
Yu Zhu, Zi Wang, Yanan Li, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1219-1219
Open Access | Times Cited: 48
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rohan Kalyan Rej, J. Thomas, Ranjan Kumar Acharyya, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8339-8381
Open Access | Times Cited: 48
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Andrea G. Shergalis, Violeta L. Marin, David Y. Rhee, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 2, pp. 331-339
Closed Access | Times Cited: 47
Design of a mucin-selective protease for targeted degradation of cancer-associated mucins
Kayvon Pedram, D. Judy Shon, Gabrielle S. Tender, et al.
Nature Biotechnology (2023) Vol. 42, Iss. 4, pp. 597-607
Open Access | Times Cited: 47
Interaction modules that impart specificity to disordered protein
Kateřina Čermáková, H. Courtney Hodges
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 5, pp. 477-490
Open Access | Times Cited: 45
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 45
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 44
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
Chuanjie Chen, Yiwen Yang, Zhe Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8428-8440
Closed Access | Times Cited: 43
AI is a viable alternative to high throughput screening: a 318-target study
Izhar Wallach, Denzil Bernard, Kong T. Nguyen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 43
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 41
Molecular hybridization: a powerful tool for multitarget drug discovery
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Tadeu L. Montagnoli, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 451-470
Closed Access | Times Cited: 40
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 37
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 31
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Xiaoting Luo, Xin He, Xingmei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 30
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Véronique Dartois, Thomas Dick
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 5, pp. 381-403
Open Access | Times Cited: 29
The neuropathobiology of multiple sclerosis
Marcel S. Woo, Jan Broder Engler, Manuel A. Friese
Nature reviews. Neuroscience (2024) Vol. 25, Iss. 7, pp. 493-513
Closed Access | Times Cited: 28
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 16, pp. 3549-3563
Open Access | Times Cited: 27
Molecular glues for protein-protein interactions: Progressing toward a new dream
Markella Konstantinidou, Michelle R. Arkin
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1064-1088
Open Access | Times Cited: 25
Roles and inhibitors of FAK in cancer: current advances and future directions
Hui-Hui Hu, Saiqi Wang, Hai-Li Shang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 24
Targeted protein degradation directly engaging lysosomes or proteasomes
Jiseong Kim, Insuk Byun, Do Young Kim, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 7, pp. 3253-3272
Open Access | Times Cited: 24

Scroll to top